BioCryst Pharmaceuticals 경영진
경영진 기준 점검 1/4
BioCryst Pharmaceuticals CEO는 Charlie Gayer, Aug2025 에 임명되었습니다 의 임기는 1.08 년입니다. 총 연간 보상은 $9.63M, 6.3% 급여 및 93.7% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $2.96M 가치에 해당하는 회사 주식의 0.14% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 1.2 년과 5 년입니다.
핵심 정보
Charlie Gayer
최고경영자
US$9.6m
총 보수
| CEO 급여 비율 | 6.33% |
| CEO 재임 기간 | 1.1yrs |
| CEO 지분 보유율 | 0.1% |
| 경영진 평균 재임 기간 | 1.2yrs |
| 이사회 평균 재임 기간 | 5yrs |
최근 경영진 업데이트
Recent updates
Seeking Alpha • Sep 11
BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity
Summary BioCryst Pharmaceuticals, Inc.'s shares remain under pressure. At the same time, Orladeyo revenue increased 6.7% QoQ to $158.2 million in the second quarter. BioCryst's royalty financing obligations declined from $465.7 million at the end of Q4 2025 to $426.8 million at the end of June. I also believe BioCryst made a smart move by acquiring navenibart, an investigational therapy for HAE. With 149%upside to the average analyst price target, I believe BCRX stock presents an attractive risk/reward profile. Read the full article on Seeking Alpha
내러티브 업데이트 • Sep 10
BCRX: Navenibart Execution Will Drive Future Upside Despite Orladeyo Headwinds
BioCryst Pharmaceuticals' analyst fair value has been revised from $12.00 to $11.00, as analysts factor in a higher discount rate, a softer revenue outlook tied to potential Orladeyo switching, and updated P/E and margin assumptions that reflect a more balanced view of near term risks and longer term opportunities around navenibart. Analyst Commentary Recent Street research on BioCryst Pharmaceuticals points to a more cautious tone, especially around the durability of Orladeyo revenues and the execution risk tied to navenibart.내러티브 업데이트 • Jul 22
BCRX: Navenibart-Focused Rare Disease Model Will Drive Long Term Upside Potential
Analysts have lowered the fair value estimate for BioCryst Pharmaceuticals to $12.00 from $14.00, citing a slightly higher discount rate, some pressure on projected profit margins, and the view that upside now leans more heavily on the success of the navenibart launch, even as firms offer supportive commentary on the long-term potential of its hereditary angioedema franchise and possible M&A interest. Analyst Commentary Recent research on BioCryst Pharmaceuticals highlights a mixed backdrop, with attention firmly on navenibart and the hereditary angioedema portfolio.내러티브 업데이트 • Jul 07
BCRX: Rare Disease Deal Interest Will Support Long Term Upside Potential
Analysts have lifted their fair value estimate for BioCryst Pharmaceuticals from $13.00 to $14.00 per share, citing higher assumed long term profit margins and ongoing interest in rare disease stocks following recent sector M&A activity and increased Street price targets, including the move to $29.00 at Cantor Fitzgerald. Analyst Commentary Recent Street research around BioCryst Pharmaceuticals has centered on how the stock fits into a broader wave of rare disease M&A and what that might mean for its valuation and execution risks.
내러티브 업데이트 • Jun 17
BCRX: Rare Disease Pipeline Progress And Licensing Deal Will Drive Shares
BioCryst Pharmaceuticals saw its consensus analyst price target raised by a few dollars into the mid $30s, as analysts pointed to updated assumptions around revenue growth, profit margins, and future P/E multiples to support their revised valuation work. Analyst Commentary Bullish analysts covering BioCryst Pharmaceuticals have recently adjusted their models and raised price targets, reflecting updated views on revenue growth assumptions, profit margins, and the P/E multiples they are willing to apply to the stock.분석 기사 • Jun 16
BioCryst (BCRX) Stock After New HAE Data Presentation Is The Undervaluation Story Still Intact
BioCryst Pharmaceuticals (BCRX) drew investor attention after presenting new clinical and real world data on its hereditary angioedema therapies ORLADEYO and navenibart at the European Academy of Allergy and Clinical Immunology meeting in Istanbul. See our latest analysis for BioCryst Pharmaceuticals. At a share price of US$9.06, BioCryst has seen short term momentum pick up around the EAACI data, with a 1 day share price return of 4.14% and year to date share price return of 20.80%. However,...
내러티브 업데이트 • Jun 02
BCRX: HAE Portfolio Progress And European Deal Will Support Upside
Analysts have nudged their price targets on BioCryst Pharmaceuticals higher, with recent Street research pointing to a combined $4 increase as they update assumptions on revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts point to updates in revenue assumptions as a key driver behind the combined US$4 increase in price targets, suggesting more confidence in the company’s ability to translate its pipeline and products into higher sales over time.내러티브 업데이트 • May 16
BCRX: Astria Integration And Licensing Deal Will Support Hereditary Angioedema Expansion
Analysts have nudged their average price target on BioCryst higher by low single digits in recent weeks, citing reiterated long-term revenue goals following the Astria Therapeutics acquisition, ongoing confidence in Orladeyo and navenibart sales potential, and steadier expectations for future profitability and P/E levels. Analyst Commentary Recent research has leaned constructive on BioCryst, with several bullish analysts adjusting their price targets upward and reaffirming confidence in the company’s long term revenue framework following the Astria Therapeutics acquisition.내러티브 업데이트 • May 01
BCRX: Astria Deal And FY26 Goals Will Support Rare Disease Upside
Analysts have inched their average price target on BioCryst Pharmaceuticals higher by $0.10 to $21.40, reflecting research that points to steady commercial execution, reiterated long term revenue goals following the Astria Therapeutics acquisition, and continued interest in the BCX17725 program as well as Orladeyo and navenibart sales potential. Analyst Commentary Recent research highlights a mix of enthusiasm and caution around BioCryst, with price targets edging higher and coverage resuming as analysts digest the Astria Therapeutics acquisition, updated guidance, and the company’s rare disease portfolio.내러티브 업데이트 • Apr 17
BCRX: Astria Integration And 2031 Debt Structure Will Support Hereditary Angioedema Expansion
Narrative Update Analysts have nudged their price targets on BioCryst Pharmaceuticals higher by $1. This reflects continued confidence in management's reiterated FY26 guidance, the integration of the Astria Therapeutics acquisition, and the longer term potential they see in Orladeyo and navenibart.내러티브 업데이트 • Apr 03
BCRX: Astria Acquisition And FY26 Guidance Will Support Long-Term Revenue Potential
Analysts lifted their price target on BioCryst Pharmaceuticals to $22 from $21, citing steady forward guidance, reaffirmed peak revenue goals following the Astria Therapeutics acquisition, and confidence in Orladeyo and the BCX17725 program as key factors supporting the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as supported by reiterated FY26 guidance and peak revenue goals, which they view as evidence that management is confident in the current growth plan.내러티브 업데이트 • Mar 20
BCRX: Astria Acquisition And FY26 Outlook Will Support Long Term Upside
Analysts lifted their price targets on BioCryst to a range of $17 to $22, citing steady FY26 guidance, reaffirmed peak revenue goals, and confidence in the Astria Therapeutics acquisition and BCX17725 data timeline as key supports for the higher valuations. Analyst Commentary Recent Street research on BioCryst highlights a mix of optimism around the Astria Therapeutics acquisition, reaffirmed FY26 guidance, and the commercial trajectory of Orladeyo, alongside growing interest in the BCX17725 program as a potential long term driver.내러티브 업데이트 • Mar 05
BCRX: Astria Acquisition And FY26 Outlook Will Support Long-Term HAE Leadership
Analysts have raised their blended price target on BioCryst Pharmaceuticals to about $21.30 from $20.50, citing reaffirmed FY26 guidance, reiterated peak revenue goals after the Astria Therapeutics acquisition, and continued confidence in the commercial ramp and the BCX17725 data timeline. Analyst Commentary Bullish Takeaways Bullish analysts see the higher blended price targets, up to about $22, as reflecting confidence in execution on the FY26 guidance and the longer term revenue framework.내러티브 업데이트 • Feb 19
BCRX: Astria Acquisition Will Drive Hereditary Angioedema Franchise Expansion
Analysts have reaffirmed their $32.00 fair value estimate for BioCryst Pharmaceuticals and supported a $17.00 price target, citing expectations for Orladeyo to potentially reach $900m in sales by 2029 and for navenibart to approach $1b in risk adjusted sales following the Astria Therapeutics acquisition. Analyst Commentary Bullish analysts view the reaffirmed US$32.00 fair value estimate and the US$17.00 price target as grounded in a clearer revenue roadmap, with both Orladeyo and navenibart framed as key building blocks of the story rather than optional upside.내러티브 업데이트 • Feb 05
BCRX: Pediatric Approval And 2031 Financing Will Strengthen Long Term Outlook
Narrative Update Overview Analysts have raised their price target on BioCryst Pharmaceuticals from US$11.00 to US$13.00, reflecting updated assumptions on revenue, profit margins, discount rate and future P/E multiples in their valuation work. What's in the News Entered a new loan agreement with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. for term loans with gross proceeds of US$400 million, issued in multiple tranches and maturing on January 23, 2031, with quarterly interest-only payments and principal due at maturity (company announcement).내러티브 업데이트 • Jan 22
BCRX: Pediatric Expansion And 2025 Profitability Outlook Will Support Long-Term HAE Leadership
Narrative Update Overview Analysts now see fair value for BioCryst Pharmaceuticals at US$20.50 per share, a US$0.10 adjustment that reflects updated assumptions on revenue growth, profit margins, discount rate, and future P/E levels. What's in the News BioCryst issued full year 2026 earnings guidance, with total revenue expected in a range of US$635 million to US$660 million (company guidance).내러티브 업데이트 • Jan 08
BCRX: Astria Acquisition Will Extend HAE Leadership With Long Acting Injectable Through 2042
Narrative Update: BioCryst Pharmaceuticals The updated analyst price target for BioCryst Pharmaceuticals has moved modestly higher to about $20.60 from $20.40, with analysts pointing to the planned $700m acquisition of Astria Therapeutics, expected SG&A synergies, and the potential of HAE candidate navenibart to support BioCryst's hereditary angioedema franchise as key reasons for their revised view. Analyst Commentary Street research around BioCryst's planned US$700m acquisition of Astria Therapeutics clusters around the same core themes, but with different levels of enthusiasm about execution risk, competitive pressure, and valuation.내러티브 업데이트 • Dec 24
BCRX: Astria Acquisition Will Extend Hereditary Angioedema Leadership Through Navenibart
We raise our BioCryst Pharmaceuticals fair value estimate to $32.00 from $28.15, as analysts highlight the accretive $700M Astria Therapeutics acquisition and its potential to extend the company’s hereditary angioedema leadership with long acting navenibart through the next decade. Analyst Commentary Analysts with a positive view on the stock are broadly endorsing BioCryst's acquisition of Astria Therapeutics, describing it as a value-accretive move that enhances the company’s hereditary angioedema portfolio and extends its potential growth runway into the 2030s and beyond.내러티브 업데이트 • Dec 10
BCRX: Astria Acquisition Will Extend HAE Leadership With Long-Acting Injectable Through 2042
Analysts have lifted their average price targets on BioCryst Pharmaceuticals by a mid-teens dollar amount into the mid to high $20s per share range, citing the proposed $700M acquisition of Astria Therapeutics as a strategically sound, earnings-accretive move that extends the company’s hereditary angioedema leadership and reduces long-term growth risk. Analyst Commentary Street research following the Astria Therapeutics deal skews constructive, with most price target revisions reflecting higher confidence in BioCryst’s long term growth profile and durability in hereditary angioedema, even as investors weigh near term dilution and competitive risks.내러티브 업데이트 • Nov 26
BCRX: Acquisition Will Extend HAE Franchise With New Long-Acting Candidate Through 2042
BioCryst Pharmaceuticals’ fair value estimate has increased from $19.73 to $20.40 per share. Analysts cite the company’s acquisition of Astria Therapeutics and improved long-term growth prospects following recent price target raises by multiple firms.내러티브 업데이트 • Nov 12
BCRX: Acquisition Will Drive Earnings Upside With New HAE Candidate Through 2042
BioCryst Pharmaceuticals' fair value estimate has been adjusted downward by approximately $0.55 per share, as analysts incorporate the strategic rationale and expected synergies following the announced acquisition of Astria Therapeutics. Analyst Commentary Market observers have provided a range of insights following BioCryst Pharmaceuticals' acquisition of Astria Therapeutics.분석 기사 • Nov 06
Earnings Beat: BioCryst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Last week saw the newest third-quarter earnings release from BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ), an...내러티브 업데이트 • Oct 29
Acquisition Of Leading HAE Therapy Candidate Will Drive Future Market Expansion
Analysts have raised their price target for BioCryst Pharmaceuticals from $18.50 to approximately $20.27 per share. This change reflects optimism about the company's acquisition of Astria Therapeutics and its anticipated impact on future growth and market position.내러티브 업데이트 • Oct 14
Expanding Rare Disease Pipeline Will Open New Markets
Analysts have raised their fair value estimate for BioCryst Pharmaceuticals to $18.50 from $16.73. They cited the anticipated long-term benefits and strategic alignment from the recent Astria Therapeutics acquisition, despite some near-term uncertainties.분석 기사 • Aug 07
BioCryst Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
A week ago, BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) came out with a strong set of quarterly numbers that could...새로운 내러티브 • May 09
ORLADEYO Pipeline Will Deliver New Therapeutic Opportunities
ORLADEYO's revenue growth, patient conversion, and reduced royalty payments enhance profitability, cash flow, and financial stability for BioCryst Pharmaceuticals.CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$385m |
| Mar 31 2026 | n/a | n/a | -US$458m |
| Dec 31 2025 | US$10m | US$609k | US$264m |
| Sep 30 2025 | n/a | n/a | -US$9m |
| Jun 30 2025 | n/a | n/a | -US$36m |
| Mar 31 2025 | n/a | n/a | -US$53m |
| Dec 31 2024 | US$3m | US$545k | -US$89m |
| Sep 30 2024 | n/a | n/a | -US$124m |
| Jun 30 2024 | n/a | n/a | -US$146m |
| Mar 31 2024 | n/a | n/a | -US$209m |
| Dec 31 2023 | US$2m | US$495k | -US$227m |
| Sep 30 2023 | n/a | n/a | -US$236m |
| Jun 30 2023 | n/a | n/a | -US$243m |
| Mar 31 2023 | n/a | n/a | -US$226m |
| Dec 31 2022 | US$2m | US$449k | -US$247m |
보상 대 시장: Charlie의 총 보수(USD9.63M)는 US 시장에서 비슷한 규모 기업의 평균(USD5.22M)보다 높습니다.
보상과 수익: Charlie의 보상은 회사가 적자임에도 증가했습니다.
CEO
Charlie Gayer (55 yo)
1.1yrs
재임 기간
US$9,627,868
보수
Mr. Charles K. Gayer, also known as Charlie, is President at BioCryst Pharmaceuticals, Inc. since August 1, 2025 and serves as its Chief Executive Officer & Director since January 01, 2026. He served as th...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO, President & Director | 1.1yrs | US$9.63m | 0.14% $ 3.0m | |
| CFO & Head of Corporate Development | 1.2yrs | US$6.75m | 데이터 없음 | |
| Senior VP | 20yrs | US$5.62m | 0.058% $ 1.2m | |
| Chief Technical Operations Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Chief Scientific Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Manager of Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Chief People Officer & Communications Officer | 1.1yrs | 데이터 없음 | 데이터 없음 | |
| Chief Development Officer | 18.2yrs | US$2.66m | 데이터 없음 | |
| Chief Discovery Officer | 12.9yrs | US$2.57m | 데이터 없음 | |
| Chief Data Innovation Officer | 4.8yrs | 데이터 없음 | 데이터 없음 | |
| Chief Strategy Officer | 4yrs | 데이터 없음 | 데이터 없음 | |
| Chief Commercial Officer | less than a year | 데이터 없음 | 0.020% $ 418.7k |
1.2yrs
평균 재임 기간
61.5yo
평균 나이
경험이 풍부한 관리: BCRX의 경영진은 경험이 부족한 것으로 간주됩니다(평균 재임 1.2 년) — 신규 팀일 수 있습니다.
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$9.63m | 0.14% $ 3.0m | |
| Independent Chairman | 5.2yrs | US$403.70k | 0.037% $ 766.1k | |
| Independent Director | 6.6yrs | US$397.50k | 0.020% $ 420.4k | |
| Independent Director | 1.3yrs | US$396.49k | 0.0079% $ 164.1k | |
| Independent Director | less than a year | 데이터 없음 | 0.0022% $ 45.9k | |
| Independent Director | 7.8yrs | US$401.70k | 0.021% $ 429.1k | |
| Director | 19.7yrs | US$12.95m | 0.41% $ 8.4m | |
| Independent Director | 5yrs | US$385.58k | 0.023% $ 473.9k | |
| Independent Director | 4.6yrs | US$385.25k | 0.0071% $ 147.3k | |
| Independent Director | 5yrs | US$390.00k | 0.013% $ 264.1k |
5.0yrs
평균 재임 기간
63.5yo
평균 나이
경험이 풍부한 이사회: BCRX의 이사회는 경험이 있음으로 간주됩니다(평균 재임 5 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/14 20:24 |
| 종가 | 2026/09/11 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
BioCryst Pharmaceuticals, Inc.는 27명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Dae Gon Ha | BTIG |
| Steven Seedhouse | Cantor Fitzgerald & Co. |